debrisoquin has been researched along with Sclerosis, Systemic in 1 studies
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| May, DG | 1 |
| Black, CM | 1 |
| Olsen, NJ | 1 |
| Csuka, ME | 1 |
| Tanner, SB | 1 |
| Bellino, L | 1 |
| Porter, JA | 1 |
| Wilkinson, GR | 1 |
| Branch, RA | 1 |
1 other study available for debrisoquin and Sclerosis, Systemic
| Article | Year |
|---|---|
Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin.
Topics: Acetylation; Adult; Biotransformation; Dapsone; Debrisoquin; Disease Susceptibility; Female; Humans; | 1990 |